Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-(1H-benzimidazol-2-yl)-1H-indazole is a synthetic small molecule belonging to the benzimidazoles class, characterized by a fused benzene and imidazole ring system attached to an indazole moiety. It has been studied as a chemical probe and potential inhibitor of viral proteases, notably the SARS-CoV main protease (also known as the "3C-like protease" or Mpro), which is essential for coronavirus replication. The compound's mechanism involves binding to and inhibiting this viral enzyme, thereby blocking viral polyprotein processing and potentially halting virus replication[9]. There are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(1H-benzimidazol-2-yl)-1H-indazole.